Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease

Current Medicinal Chemistry
Francesca ReF Nicotra

Abstract

The progressive production and subsequent accumulation of β-amyloid (Aβ), a proteolytic fragment of the membrane-associated amyloid precursor protein (APP), plays a central role in Alzheimer's Disease (AD). Aβ is released in a soluble form that may be responsible for cognitive dysfunction in the early stages of the disease, then progressively forms oligomeric, multimeric and fibrillar aggregates, triggering neurodegeneration. Eventually, the aggregation and accumulation of Aβ culminates with the formation of extracellular plaques, one of the morphological hallmarks of the disease, detectable post-mortem in AD brains. In this review we report the known structural features of amyloid peptides and fibrils, and we give an overview of all small molecules that have been found to interact with Aβ aggregation. Deeper knowledge of the mechanism leading to amyloid fibrils along with their molecular structure and the molecular interactions responsible for activity of small molecules could supply useful information for the design of new AD therapeutic agents.

Citations

Dec 22, 2011·Journal of Medicinal Chemistry·Carles GaldeanoDiego Muñoz-Torrero
Sep 27, 2012·Journal of Medicinal Chemistry·Laura C LópezJavier Sancho
Aug 23, 2011·Chemical Communications : Chem Comm·Cristina AiroldiBarbara La Ferla
Jan 19, 2012·The Journal of Biological Chemistry·Xueyun ZhengMichael T Bowers
Oct 5, 2011·The Journal of Biological Chemistry·Marino ConvertinoAmedeo Caflisch
May 30, 2013·International Journal of Nanomedicine·Antonina OrlandoEmanuela Cazzaniga
Jan 10, 2016·The Journal of Chemical Physics·Manikanthan BhavarajuUlrich H E Hansmann
Aug 3, 2011·Journal of Biotechnology·Cristina AiroldiBarbara La Ferla
Nov 28, 2014·IET Nanobiotechnology·Jian PengLi-Ping Sun
Oct 24, 2012·The International Journal of Biochemistry & Cell Biology·Mehrnaz Azami-MovahedMohsen Nemat-Gorgani
May 7, 2016·ACS Applied Materials & Interfaces·Sayan Roy ChowdhuryParameswar Krishnan Iyer
May 4, 2017·PloS One·Dharmeshkumar Patel, Serdar Kuyucak
Apr 17, 2018·Chemical Communications : Chem Comm·Rashik Ahmed, Giuseppe Melacini
Feb 13, 2018·Biological Reviews of the Cambridge Philosophical Society·Arun Upadhyay, Amit Mishra
Oct 5, 2018·Organic & Biomolecular Chemistry·Madhu RameshThimmaiah Govindaraju
May 3, 2019·Advanced Materials·Fei-He MaLinqi Shi
Jan 15, 2020·Current Pharmaceutical Design·Daniela Jara-MorenoCarla Delporte
Jan 26, 2013·Journal of Peptide Science : an Official Publication of the European Peptide Society·Wei ZhangJianting Miao
Aug 13, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Karla Martinez PomierGiuseppe Melacini
Jun 1, 2013·Advanced Materials·Min ZhangChen Wang
May 31, 2017·Neuroscience Bulletin·Aihua YangChen Wang
Dec 6, 2019·Frontiers in Aging Neuroscience·Marcella CataniaGiuseppe Di Fede
Jul 5, 2012·Annals of the New York Academy of Sciences·Emanuela MaioliGiuseppe Valacchi
Apr 7, 2018·Chemistry : a European Journal·Valentina OliveriGraziella Vecchio
Nov 11, 2019·International Journal of Molecular Sciences·Hassan RamshiniFabrizio Chiti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.